2011
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis
Dangas GD, Mehran R, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möckel M, Caixeta A, Parise H, White H, Stone GW, Investigators H. Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis. Journal Of The American College Of Cardiology 2011, 57: 2309-2316. PMID: 21636031, DOI: 10.1016/j.jacc.2011.01.038.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionMajor bleedingMyocardial infarctionCardiac mortalityAcute ST-segment elevation myocardial infarctionST-segment elevation myocardial infarction (STEMI) patientsPrimary Percutaneous Coronary Intervention ResultsGlycoprotein IIb/IIIa inhibitorsPercutaneous Coronary Intervention ResultsElevation myocardial infarction patientsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBenefit of bivalirudinLate cardiac survivalProbable stent thrombosisPercutaneous coronary interventionTwo-year rateAcute myocardial infarctionMyocardial infarction patientsHORIZONS-AMISwitch patientsPrimary angioplastyControl patientsCoronary intervention
2007
Impact of Time to Treatment on Myocardial Reperfusion and Infarct Size With Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the EMERALD Trial)
Brodie BR, Webb J, Cox DA, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford B, Antoniucci D, Stuckey T, Krucoff M, Gibbons R, Lansky A, Na Y, Mehran R, Stone GW, Investigators E. Impact of Time to Treatment on Myocardial Reperfusion and Infarct Size With Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the EMERALD Trial). The American Journal Of Cardiology 2007, 99: 1680-1686. PMID: 17560875, DOI: 10.1016/j.amjcard.2007.01.047.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPrimary PCIPercutaneous coronary interventionSmaller infarct sizeInfarct sizeNonanterior infarctionDistal protectionCoronary interventionMyocardial infarctionST-elevation myocardial infarctionHigh-risk patientsTriage of patientsAcute myocardial infarctionEMERALD trialImpact of timeControl patientsEarly reperfusionMyocardial reperfusionClinical outcomesAnterior infarctionMyocardial blushReperfusionInfarctionMortality ratePatients
2005
Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation An intravascular ultrasound study
Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation An intravascular ultrasound study. Journal Of The American College Of Cardiology 2005, 45: 995-998. PMID: 15808753, DOI: 10.1016/j.jacc.2004.12.066.Peer-Reviewed Original ResearchConceptsSirolimus-eluting stent implantationMinimum stent cross-sectional areaSuccessful SES implantationStent thrombosisSegment stenosisStent thrombosis groupStent underexpansionSES implantationThrombosis groupControl patientsStent implantationStent cross-sectional areaIntravascular ultrasound studyIndependent predictorsUltrasound studyThrombosisDrug AdministrationControl groupNumber of casesStenosisStent expansionPatientsU.S. FoodUnderexpansionCross-sectional areaCreatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque
Fujii K, Carlier SG, Mintz GS, Kobayashi Y, Jacoboff D, Nierenberg H, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, Stone GW, Leon MB, Moses JW. Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque. The American Journal Of Cardiology 2005, 95: 355-359. PMID: 15670544, DOI: 10.1016/j.amjcard.2004.09.033.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceCase-Control StudiesChi-Square DistributionCineangiographyCoronary AngiographyCoronary Artery DiseaseCreatine KinaseCreatine Kinase, MB FormFemaleHumansImage Processing, Computer-AssistedIsoenzymesMaleMiddle AgedRuptureStatistics, NonparametricStentsUltrasonography, InterventionalConceptsAcute coronary syndromeCoronary syndromeCoronary stentingClinical outcomesStent implantationRuptured plaquesCreatine kinase-MB isoenzyme releaseCreatine kinase‐MB enzyme elevationLong-term clinical eventsCK-MB elevationCK-MB releaseSuccessful coronary stentingControl patientsUnstable anginaEnzyme elevationIndependent predictorsProcedural complicationsClinical eventsPlaque ruptureIntravascular ultrasoundPatientsLong-term eventsPlaquesComposite rateSyndrome
2004
Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial)
Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, Stone GW, Investigators F. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). The American Journal Of Cardiology 2004, 94: 983-988. PMID: 15476608, DOI: 10.1016/j.amjcard.2004.06.050.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPercutaneous coronary interventionAcute myocardial infarctionMajor adverse cardiac eventsAdverse cardiac eventsEarly thrombosisAbciximab usePrimary stentingPrimary angioplastyCardiac eventsBalloon angioplastyMyocardial infarctionBalloon diameterLate Angioplasty Complications (CADILLAC) trialRepeat target vessel revascularizationRepeat coronary angioplastyTarget vessel revascularizationHigh rateControlled AbciximabVessel revascularizationAngiographic morphologyClinical determinantsComplications TrialControl patientsCoronary intervention
2003
Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries
Stone GW, Cox DA, Babb J, Nukta D, Bilodeau L, Cannon L, Stuckey TD, Hermiller J, Cohen EA, Low R, Bailey SR, Lansky AJ, Kuntz RE, Investigators F. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. Journal Of The American College Of Cardiology 2003, 42: 2007-2013. PMID: 14662267, DOI: 10.1016/j.jacc.2003.10.001.Peer-Reviewed Original ResearchConceptsDiseased saphenous vein graftsSaphenous vein graftsNative coronary arteriesPeri-procedural myocardial infarctionEvent-free survivalCoronary arteryMyocardial infarctionControl patientsStent implantationRoutine thrombectomyVein graftsSize patientsLate event-free survivalMajor adverse cardiac eventsPeri-procedural myonecrosisAdverse cardiac eventsHigh-risk patientsPercutaneous coronary interventionLarge myocardial infarctionSafety of interventionsPrior thrombectomyCardiac eventsCoronary interventionPercutaneous interventionLate outcomesOutcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial)
Ashby DT, Aymong EA, Tcheng JE, Grines CL, Cox DA, Mehran R, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Lansky AJ, Stone GW. Outcomes following Bail-Out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). The American Journal Of Cardiology 2003, 92: 1091-1094. PMID: 14583362, DOI: 10.1016/j.amjcard.2003.06.005.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCross-Over StudiesDrug Administration ScheduleFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsIntraoperative ComplicationsMaleMiddle AgedMyocardial InfarctionPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesTreatment FailureConceptsAcute myocardial infarctionMyocardial infarctionGlycoprotein IIb/IIIa receptor inhibitorsUnsuccessful primary percutaneous coronary interventionIIb/IIIa receptor inhibitorsMyocardial Infarction (TIMI) grade 3 flowPrimary percutaneous coronary interventionGrade 3 flowPercutaneous coronary interventionSuboptimal angioplasty resultsAbciximab administrationCADILLAC trialIschemic complicationsControl patientsCoronary interventionProcedural complicationsAngioplasty resultsReceptor inhibitorsPrimary interventionAbciximabPatientsComplicationsInfarctionLower ratesIntervention